VolitionRx reports Q3 revenue $600,000, consensus $715,590

Net loss was down 8% for the quarter and down 20% for the first three quarters compared to the prior year. Cameron Reynolds, President and Group Chief Executive Officer, said: “2025 efforts for Volition focused on commercializing our groundbreaking Nu.Q platform in the human diagnostics market and we were excited this quarter to sign not one, but two human agreements: a Research License and Exclusive Commercial Option Rights Agreement for Antiphospholipid Syndrome with Werfen and a Co-Marketing and Services Agreement with Hologic. Both are multi-billion dollar companies, and worldwide leaders in their specialized fields, and we are delighted to report that both have very much hit the ground running. We are in discussions with around 10 of the world’s leading diagnostic and liquid biopsy companies and are at various stages of the process across our different pillars, ranging from due diligence to tech transfer, to evaluation of clinical samples, to term sheet and contract negotiation. We anticipate further human licensing deals with a range of large companies and will update on progress as they are completed. We believe that our positive emerging clinical evidence supports the broad applicability of our Nu.Q technology in critical areas such as cancer and sepsis, including as a biomarker of interest to epigenetic drug development, an ever expanding area of focus for big pharma. We have made significant progress on several publications in recent months and anticipate peer-reviewed publications across all pillars in the coming quarters, including our ground-breaking Capture-Seq technology. We believe the ability to concentrate chromatin fragments and therefore tumor DNA, has great potential in the liquid biopsy field. Our goal is to secure a range of licensing agreements in the human diagnostics space, mirroring our successful strategy in the veterinary market, and anticipate, similar to the veterinary market, diverse deal structures, with potential for up front and milestone payments, and future recurring revenue. We believe we have developed a unique and widely applicable platform that will contribute significantly to oncology and NETosis detection and monitoring for decades to come, and for hundreds of millions of people and animals worldwide.”